Tag: Metastatic Prostate Cancer

PCa17: What to expect in future prostate cancer management

The number of promising biomarkers at different molecular levels are increasing, accompanied by numerous testing in the market, but cancer experts say independent and prospective validation is crucial to help the medical community eventually provide optimal care to cancer...

PCa17: Interactive, compact meeting opens in Vienna

Challenges in diagnosis, staging and patient selection were among the issues taken up in the first plenary session of the EAU Update on Prostate Cancer (PCa17) opened in Vienna today. With more than 300 participants including faculty and exhibitors,...

BALTIC17 looks into best practices in uro-oncology

Vilnius welcomed more than 250 participants to the 4th Baltic Meeting (BALTIC17) with the opening session focusing on best and current practices in diagnosing and managing urological cancers particularly the role of biopsy techniques, imaging tools, quality of life...

EMUC16: National cancer prevention plans need a boost

National cancer plans, which are vital for an effective pan-European cancer care programme, should look closer at prevention, rehabilitation and survivorship issues, according to a public healthcare expert who spoke at the 8th European Multidisciplinary Meeting on Urological Cancers...

EMUC16: Re-thinking active surveillance strategies in PCa

With the emergence of more precise imaging and new results from genomic investigations, onco-urology experts are challenging standard medical strategies and are re-thinking their treatment regimens to achieve better patient care. At the concluding session of the 8th European...

EMUC16: Consequences of pelvic radiotherapy

Urological cancer experts were warned on the far-reaching consequences of high-dosage radiation therapy with a dedicated session that examined the complications and clinical management of radiation-related pelvic cancers held today at the 8th European Meeting on Urological Cancers (EMUC16)...

EMUC16: Imaging and the treatment landscape for recurrent PCa

Current and prospective treatment strategies that employ image-guided approaches for prostate cancer recurrences were examined with experts exploring options in radiotherapy, surgery and chemotherapy. Speakers Steven Joniau (BE), Barbara Jereczek-Fossa (IT), George Thalmann (CH) and Cora Sternberg (IT) presented...

EMUC16: Experts tackle combined therapies in prostate cancer

Systemic treatments and optimizing various forms of therapies in high-risk and metastatic forms of prostate cancer were examined at the first-day plenary session of the 8th European Meeting on Urological Cancers (EMUC16) which opened today in Milan, Italy. With...

CEM16: Romanian study identifies two SNPs linked to PCa

A Romanian study identified two single nucleotide polymorphisms (SNPs) that were linked to a significant risk for high-grade prostate cancer tumours, according to an award-winning poster presented at the 16th Central European Meeting (CEM16) held over the weekend in...

BALTIC16: Expert warns of drug resistance in mCRPC patients

Although there are small gains in providing hormone and chemotherapy to metastatic castration-resistant prostate cancer (mCRPC) patient, experts cautioned that the increased use of these new agents may lead to new patterns of resistance. “With increasing use of novel...